1.16
4.50%
0.05
Handel nachbörslich:
1.20
0.04
+3.45%
Schlusskurs vom Vortag:
$1.11
Offen:
$1.15
24-Stunden-Volumen:
1.83M
Relative Volume:
0.37
Marktkapitalisierung:
$134.43M
Einnahmen:
$257.24M
Nettoeinkommen (Verlust:
$-237.89M
KGV:
-0.4462
EPS:
-2.6
Netto-Cashflow:
$-175.17M
1W Leistung:
+4.50%
1M Leistung:
-30.12%
6M Leistung:
-14.07%
1J Leistung:
-43.69%
Coherus Biosciences Inc Stock (CHRS) Company Profile
Firmenname
Coherus Biosciences Inc
Sektor
Branche
Telefon
(650) 649-3530
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Vergleichen Sie CHRS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
CHRS
Coherus Biosciences Inc
|
1.16 | 134.43M | 257.24M | -237.89M | -175.17M | -2.60 |
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-08-16 | Herabstufung | UBS | Buy → Neutral |
2023-11-17 | Eingeleitet | Robert W. Baird | Outperform |
2023-11-08 | Herabstufung | Maxim Group | Buy → Hold |
2023-07-24 | Eingeleitet | Citigroup | Buy |
2023-05-01 | Eingeleitet | Truist | Buy |
2023-03-28 | Hochstufung | UBS | Neutral → Buy |
2022-06-14 | Eingeleitet | UBS | Neutral |
2022-03-07 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-07-16 | Eingeleitet | BofA Securities | Neutral |
2020-04-17 | Eingeleitet | SunTrust | Buy |
2019-08-13 | Eingeleitet | Mizuho | Buy |
2019-08-02 | Bestätigt | H.C. Wainwright | Buy |
2019-08-02 | Bestätigt | Maxim Group | Buy |
2019-06-11 | Eingeleitet | Barclays | Overweight |
2019-05-07 | Eingeleitet | H.C. Wainwright | Buy |
2018-08-28 | Eingeleitet | H.C. Wainwright | Buy |
2018-03-09 | Bestätigt | Maxim Group | Buy |
2017-08-08 | Bestätigt | JP Morgan | Overweight |
2017-06-13 | Bestätigt | Maxim Group | Buy |
2017-05-05 | Eingeleitet | BMO Capital Markets | Outperform |
2016-10-19 | Eingeleitet | Robert W. Baird | Outperform |
2016-09-07 | Eingeleitet | Maxim Group | Buy |
2016-07-27 | Eingeleitet | Citigroup | Buy |
2016-01-20 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Coherus Biosciences Inc Aktie (CHRS) Neueste Nachrichten
Coherus BioSciences's SWOT analysis: stock faces headwinds amid oncology pivot - MSN
Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright - MarketBeat
Positive Phase II trial results for Coherus' casdozokitug - The Pharma Letter
Coherus Presents Final Phase 2 Clinical Casdozokitug - GlobeNewswire
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with ... - The Bakersfield Californian
CHRS (Coherus BioSciences) Market Cap : $160.1 Mil (As of Jan. 21, 2025) - GuruFocus.com
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Coherus BioSciences (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise - Simply Wall St
Coherus to Present Final Phase 2 Casdozokitug Combination - GlobeNewswire
Coherus BioSciences to Present Groundbreaking Cancer Treatment Data at ASCO-GI 2025 - StockTitan
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development - Seeking Alpha
Short Interest in Coherus BioSciences, Inc. (NASDAQ:CHRS) Drops By 7.0% - MarketBeat
Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition - Investing.com
Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Coherus BioSciences to divest UDENYCA franchise for up to $558.4M - MSN
Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Disciplined Growth Investors Inc. MN - MarketBeat
California-Based Biotech Rallies Strongly Following $558.4M Divestiture - MSN
Coherus price target raised at Baird on agreement to sell Udenyca - Investing.com Canada
Coherus BioSciences director Tzoumakas to exit board By Investing.com - Investing.com Canada
Coherus BioSciences director Tzoumakas to exit board - Investing.com
Intas acquires Udenyca from Coherus BioSciences in potential $558 million deal - BioProcess Insider
Coherus BioSciences (FRA:8C5) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
CHRS (Coherus BioSciences) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Coherus Biosciences Announces Board Member Resignation - TipRanks
Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition By Investing.com - Investing.com Australia
Latham Watkins Advises Coherus in Divesture of UDENYCA Franchise to Intas Pharmaceuticals - Latham & Watkins LLP
Accord acquires Coherus’ Udenyca business - The Pharma Letter
Intas to acquire Coherus’ Udenyca assets for up to $558m - World Pharmaceutical Frontiers
Goodbye Biosimilars: Coherus Sells Udenyca To Intas For Half A Billion - News & Insights
S&P 500 Total Return (TCM23) Quote - The Globe and Mail
Intas Pharma to acquire Udenyca business from Coherus BioSciences - Medical Dialogues
Coherus Continues Funding IO Ambitions By Offloading Biosimilars - News & Insights
TSX Consumer Discretionary Capped Index (TTCD) QuotePress Release - The Globe and Mail
TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail
Redwood City-based Coherus' stock surges after major drug sale - The Business Journals
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Raleigh pharmaceutical company expands portfolio with $558M deal - The Business Journals
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M - BioPharma Dive
Coherus unloads Udenyca in $558M deal to power immuno-oncology ambitions - FirstWord Pharma
Coherus shares surge on $558M Udenyca divestiture deal By Investing.com - Investing.com South Africa
Coherus shares surge on $558M Udenyca divestiture deal - Investing.com
Unusually active option classes on open December 3rd - TipRanks
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth - The Malaysian Reserve
Why Is Coherus BioSciences Stock Trading Higher On Tuesday? - Inkl
Coherus Biosciences agrees to divest UDENYCA franchise for up to $558M - TipRanks
Coherus Bio jumps on deal to divest biosimilar of Amgen's Neulasta - XM
Finanzdaten der Coherus Biosciences Inc-Aktie (CHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):